B细胞可导致免疫介导的疾病。靶向CD20已被证明在几种B细胞介导的免疫病理学中是有效的,如利妥昔单抗的使用所示,第一个抗CD20单克隆抗体(mAb)。利妥昔单抗之后,第二代和第三代抗CD20单克隆抗体已被开发并尝试用于免疫介导的疾病,包括奥比努珠单抗,奥克瑞珠单抗,Ofatumumab,ublituximab,和veltuzumab.然而,其安全性和有效性尚未进行系统评价.
为了评估奥比努珠单抗的安全性和有效性,奥克瑞珠单抗,Ofatumumab,ublituximab,与安慰剂相比,veltuzumab用于治疗免疫介导的疾病,常规治疗或其他生物制剂。
PRISMA检查表指导了数据的报告。我们在2016年10月4日至2021年7月22日期间搜索了PubMed数据库,重点关注免疫介导的疾病。
文献检索确定了2220篇文章。在根据纳入和排除标准筛选标题和摘要并评估全文后,27篇文章最终被纳入叙事综合。
Obinutuzumab在一系列磷脂酶A2受体相关膜性肾病患者和系统性红斑狼疮患者的混合结果中显示出了有希望的结果。Ocrelizumab已被批准用于复发缓解型多发性硬化症和原发性进行性多发性硬化症患者。Ocrelizumab还在类风湿关节炎患者中进行了测试,展示了有希望的结果,在系统性红斑狼疮中,揭示了好坏参半的结果;然而,在这些条件下,其使用与严重感染风险增加相关.Ofatumumab获得批准用于治疗复发缓解型多发性硬化症患者。此外,Ofatumumab在抗中性粒细胞胞浆抗体相关性血管炎患者中显示出有希望的结果,类风湿性关节炎,系统性红斑狼疮,以及磷脂酶A2受体相关膜性肾病的混合结果。Ublituximab在复发缓解型多发性硬化症和视神经脊髓炎谱系疾病中进行了评估,有希望的结果,然而,纳入的患者数量太少而无法得出结论.Veltuzumab在免疫性血小板减少症患者中进行了测试,从而改善了血小板计数。
https://www。crd.约克。AC.英国/普华永道/,标识符CRD4201113421。
B cells can contribute to immune-mediated disorders. Targeting CD20 has proved to be efficacious in several B cell-mediated immunopathologies, as illustrated by the use of rituximab, the first anti-CD20 monoclonal antibody (mAb). Following rituximab, second- and third-generation anti-CD20 mAbs have been developed and tried in immune-mediated diseases, including
obinutuzumab, ocrelizumab, ofatumumab, ublituximab, and veltuzumab. However, their safety and efficacy has not been systematically reviewed.
To evaluate safety and efficacy of
obinutuzumab, ocrelizumab, ofatumumab, ublituximab, and veltuzumab for the treatment of immune-mediated disorders compared to placebo, conventional treatment or other biologics.
The PRISMA checklist guided the reporting of the data. We searched the PubMed database between 4 October 2016 and 22 July 2021 concentrating on immune-mediated disorders.
The literature search identified 2220 articles. After screening titles and abstracts against the inclusion and exclusion criteria and assessing full texts, 27 articles were finally included in a narrative synthesis.
Obinutuzumab has shown promising results in a case series of patients with phospholipase A2 receptor-associated membranous nephropathy and mixed results in systemic lupus erythematosus. Ocrelizumab has been approved for the use in patients with relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis. Ocrelizumab was also tested in patients with rheumatoid arthritis, demonstrating promising results, and in systemic lupus erythematosus, revealing mixed results; however, in these conditions, its use was associated with increased risk of serious infections. Ofatumumab received approval for treating patients with relapsing-remitting multiple sclerosis. Moreover, ofatumumab showed promising results in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis, rheumatoid arthritis, and systemic lupus erythematosus, as well as mixed results in phospholipase A2 receptor-associated membranous nephropathy. Ublituximab was assessed in relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorder, with promising results, however, the included number of patients was too small to conclude. Veltuzumab was tested in patients with immune thrombocytopenia resulting in improved platelet counts.
https://www.crd.york.ac.uk/prospero/, identifier CRD4201913421.